Denver, CO 的 乳癌 臨床試驗
29 項針對 乳癌 的研究正在 Denver（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
The Vanguard Study: Testing a New Way to Screen for Cancer
招募中歡迎健康志工
- Kaiser Permanente-Franklin, Denver
A Study of PHST001 in Advanced Solid Tumors
招募中1 期
- Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One, Denver
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
招募中1/2 期
- Rocky Mountain Cancer Center, Denver
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
招募中3 期
- Rocky Mountain Cancer Centers, Denver
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中觀察性研究歡迎健康志工
- AdventHealth Porter, Denver
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
招募中2 期
- Rocky Mountain Cancer Centers, Denver
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
招募中1 期
- Sarah Cannon Research Institute (Scri) At Health One, Denver
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
招募中3 期
- UCHealth Cherry Creek Medical Center ( Site 0094), Denver
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
招募中3 期
- Research Site, Denver
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
招募中3 期
- UCHealth Cherry Creek Medical Center, Denver
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
招募中2 期
- Saint Joseph Hospital - Cancer Centers of Colorado, Denver
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
招募中3 期
- Intermountain Health Cancer Center Saint Joseph ( Site 0062), Denver
- Rocky Mountain Cancer Centers (RMCC) ( Site 8006), Denver
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
招募中3 期
- Clinical Trial Site, Denver
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
招募中3 期
- St. Joseph Hospital-Cancer Centers of Colorado, Denver
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
招募中1/2 期
- Skin Cancer Institute, Englewood · 距離 6 英里
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
招募中3 期
- UCHealth - Cherry Creek, Denver
- Saint Joseph Hospital - Cancer Centers of Colorado, Denver
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
招募中1 期
- Sarah Cannon Research Institute at HealthONE, Denver
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
招募中1 期
- Sarah Cannon Research Institute - Denver DDU, Denver
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
招募中1 期
- Sarah Cannon Research Institute (SCRI) at HealthONE-Denver, Denver
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
招募中2/3 期
- Rocky Mountain Cancer Centers, Denver
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
招募中3 期
- Rocky Mountain Cancer Centers, Denver
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
招募中1/2 期
- Sarah Cannon Research Institute, Denver
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
招募中3 期
- Rocky Mountain Cancer Centers LLP, Denver
- Rocky Mountain Cancer Centers LLP, Englewood · 距離 6 英里
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
招募中3 期
- UCHealth - Cherry Creek, Denver
- Rose Medical Center, Denver
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
招募中觀察性研究
- Kaiser Permanente-Franklin, Denver
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Centers-Midtown, Denver
- 還有 1 項
The Immune System's Response to Young Women's Breast Cancer
招募中觀察性研究
- Denver Health Hospital Authority, Denver
- UCHealth Cherry Creek Medcial Center, Denver
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Denver
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
招募中1 期
- HealthONE, Denver
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
招募中觀察性研究
- Comprehensive Breast Care of Denver, Denver
其他城市的 乳癌 試驗
- New York City, NY136 項研究
- Houston, TX126 項研究
- Boston, MA112 項研究
- Nashville, TN81 項研究
- Los Angeles, CA73 項研究
- Edison, NJ68 項研究
- St. Louis, MO64 項研究
- Queens, NY64 項研究
- Durham, NC64 項研究
- Chicago, IL59 項研究
- Philadelphia, PA56 項研究
- Dallas, TX55 項研究
Denver 的其他研究
- 轉移性癌症29 項研究
- 非小細胞肺癌27 項研究
- 多發性骨髓瘤27 項研究
- 大腸直腸癌23 項研究
- 黑色素瘤19 項研究
- 前列腺癌19 項研究
- 癌症（所有類型）18 項研究
- 卵巢癌16 項研究
- 肺癌16 項研究
- 子宮內膜癌15 項研究
- 非霍奇金淋巴瘤14 項研究
- 胰臟癌13 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。